This company has been marked as potentially delisted and may not be actively trading.

Paragon 28 (FNA) Competitors

FNA vs. NVST, IRTC, TMDX, LQDA, and MMED

Should you be buying Paragon 28 stock or one of its competitors? The main competitors of Paragon 28 include Envista (NVST), iRhythm Technologies (IRTC), TransMedics Group (TMDX), Liquidia (LQDA), and MiniMed Group (MMED). These companies are all part of the "medical equipment" industry.

How does Paragon 28 compare to Envista?

Envista (NYSE:NVST) and Paragon 28 (NYSE:FNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

: Envista has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
: In the previous week, Envista had 19 more articles in the media than Paragon 28. MarketBeat recorded 19 mentions for Envista and 0 mentions for Paragon 28. Envista's average media sentiment score of 0.56 beat Paragon 28's score of 0.00 indicating that Envista is being referred to more favorably in the media.
Company Overall Sentiment
Envista Positive
Paragon 28 Neutral
: Envista has a net margin of 2.41% compared to Paragon 28's net margin of -25.31%. Envista's return on equity of 7.09% beat Paragon 28's return on equity.
Company Net Margins Return on Equity Return on Assets
Envista 2.41% 7.09% 3.90%
Paragon 28 -25.31% -37.90% -18.22%
: Envista has higher revenue and earnings than Paragon 28. Paragon 28 is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Envista $2.72B 1.46 $47M $0.28 87.18
Paragon 28 $256.18M 4.29 -$57.53M -$0.63 N/A
: Envista currently has a consensus target price of $28.83, indicating a potential upside of 18.12%. Given Envista's stronger consensus rating and higher possible upside, equities analysts clearly believe Envista is more favorable than Paragon 28.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Envista
0 Sell rating(s)
9 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.40
Paragon 28
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 63.6% of Paragon 28 shares are held by institutional investors. 1.0% of Envista shares are held by insiders. Comparatively, 15.3% of Paragon 28 shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Overall Sentiment
Envista	Positive
Paragon 28	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.09%	3.90%
Paragon 28	-25.31%	-37.90%	-18.22%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.72B	1.46	$47M	$0.28	87.18
Paragon 28	$256.18M	4.29	-$57.53M	-$0.63	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	9 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.40
Paragon 28	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Envista beats Paragon 28 on 12 of the 16 factors compared between the two stocks.

How does Paragon 28 compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Paragon 28 (NYSE:FNA) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation, institutional ownership and media sentiment.

: iRhythm Technologies has a net margin of -3.53% compared to Paragon 28's net margin of -25.31%. iRhythm Technologies' return on equity of -10.26% beat Paragon 28's return on equity.
Company Net Margins Return on Equity Return on Assets
iRhythm Technologies -3.53% -10.26% -1.39%
Paragon 28 -25.31% -37.90% -18.22%
: iRhythm Technologies has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500.
: iRhythm Technologies has higher revenue and earnings than Paragon 28. iRhythm Technologies is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
iRhythm Technologies $747.14M 5.49 -$44.55M -$0.86 N/A
Paragon 28 $256.18M 4.29 -$57.53M -$0.63 N/A
: iRhythm Technologies currently has a consensus target price of $193.38, indicating a potential upside of 54.87%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, equities analysts clearly believe iRhythm Technologies is more favorable than Paragon 28.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
iRhythm Technologies
1 Sell rating(s)
1 Hold rating(s)

11 Buy rating(s)

2 Strong Buy rating(s)
2.93
Paragon 28
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: In the previous week, iRhythm Technologies had 27 more articles in the media than Paragon 28. MarketBeat recorded 27 mentions for iRhythm Technologies and 0 mentions for Paragon 28. iRhythm Technologies' average media sentiment score of 0.52 beat Paragon 28's score of 0.00 indicating that iRhythm Technologies is being referred to more favorably in the media.
Company Overall Sentiment
iRhythm Technologies Positive
Paragon 28 Neutral
: 63.6% of Paragon 28 shares are held by institutional investors. 1.0% of iRhythm Technologies shares are held by insiders. Comparatively, 15.3% of Paragon 28 shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-3.53%	-10.26%	-1.39%
Paragon 28	-25.31%	-37.90%	-18.22%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.49	-$44.55M	-$0.86	N/A
Paragon 28	$256.18M	4.29	-$57.53M	-$0.63	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Paragon 28	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Company	Overall Sentiment
iRhythm Technologies	Positive
Paragon 28	Neutral

Summary

iRhythm Technologies beats Paragon 28 on 12 of the 17 factors compared between the two stocks.

How does Paragon 28 compare to TransMedics Group?

Paragon 28 (NYSE:FNA) and TransMedics Group (NASDAQ:TMDX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.

: TransMedics Group has a net margin of 27.04% compared to Paragon 28's net margin of -25.31%. TransMedics Group's return on equity of 22.38% beat Paragon 28's return on equity.
Company Net Margins Return on Equity Return on Assets
Paragon 28 -25.31% -37.90% -18.22%
TransMedics Group 27.04% 22.38% 8.46%
: Paragon 28 has a beta of 1.47, indicating that its stock price is 47% more volatile than the S&P 500. Comparatively, TransMedics Group has a beta of 2.07, indicating that its stock price is 107% more volatile than the S&P 500.
: TransMedics Group has higher revenue and earnings than Paragon 28. Paragon 28 is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Paragon 28 $256.18M 4.29 -$57.53M -$0.63 N/A
TransMedics Group $605.49M 4.16 $190.29M $4.90 14.88
: TransMedics Group has a consensus target price of $135.00, suggesting a potential upside of 85.19%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts plainly believe TransMedics Group is more favorable than Paragon 28.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Paragon 28
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
TransMedics Group
0 Sell rating(s)

6 Hold rating(s)

6 Buy rating(s)

0 Strong Buy rating(s)
2.50
: In the previous week, TransMedics Group had 31 more articles in the media than Paragon 28. MarketBeat recorded 31 mentions for TransMedics Group and 0 mentions for Paragon 28. Paragon 28's average media sentiment score of 0.00 beat TransMedics Group's score of -0.35 indicating that Paragon 28 is being referred to more favorably in the media.
Company Overall Sentiment
Paragon 28 Neutral
TransMedics Group Neutral
: 63.6% of Paragon 28 shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 15.3% of Paragon 28 shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Paragon 28	-25.31%	-37.90%	-18.22%
TransMedics Group	27.04%	22.38%	8.46%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paragon 28	$256.18M	4.29	-$57.53M	-$0.63	N/A
TransMedics Group	$605.49M	4.16	$190.29M	$4.90	14.88

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paragon 28	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
TransMedics Group	0 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Overall Sentiment
Paragon 28	Neutral
TransMedics Group	Neutral

Summary

TransMedics Group beats Paragon 28 on 13 of the 16 factors compared between the two stocks.

How does Paragon 28 compare to Liquidia?

Paragon 28 (NYSE:FNA) and Liquidia (NASDAQ:LQDA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

: In the previous week, Liquidia had 11 more articles in the media than Paragon 28. MarketBeat recorded 11 mentions for Liquidia and 0 mentions for Paragon 28. Liquidia's average media sentiment score of 0.40 beat Paragon 28's score of 0.00 indicating that Liquidia is being referred to more favorably in the news media.
Company Overall Sentiment
Paragon 28 Neutral
Liquidia Neutral
: Paragon 28 has a beta of 1.47, indicating that its share price is 47% more volatile than the S&P 500. Comparatively, Liquidia has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500.
: Paragon 28 has a net margin of -25.31% compared to Liquidia's net margin of -43.53%. Paragon 28's return on equity of -37.90% beat Liquidia's return on equity.
Company Net Margins Return on Equity Return on Assets
Paragon 28 -25.31% -37.90% -18.22%
Liquidia -43.53% -209.33% -25.32%
: Paragon 28 has higher revenue and earnings than Liquidia. Liquidia is trading at a lower price-to-earnings ratio than Paragon 28, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Paragon 28 $256.18M 4.29 -$57.53M -$0.63 N/A
Liquidia $158.32M 23.74 -$68.92M -$0.83 N/A
: 63.6% of Paragon 28 shares are held by institutional investors. Comparatively, 64.5% of Liquidia shares are held by institutional investors. 15.3% of Paragon 28 shares are held by company insiders. Comparatively, 25.6% of Liquidia shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
: Liquidia has a consensus target price of $43.44, suggesting a potential upside of 2.75%. Given Liquidia's stronger consensus rating and higher probable upside, analysts clearly believe Liquidia is more favorable than Paragon 28.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Paragon 28
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Liquidia
2 Sell rating(s)

0 Hold rating(s)

7 Buy rating(s)

3 Strong Buy rating(s)
2.92

Company	Overall Sentiment
Paragon 28	Neutral
Liquidia	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Paragon 28	-25.31%	-37.90%	-18.22%
Liquidia	-43.53%	-209.33%	-25.32%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paragon 28	$256.18M	4.29	-$57.53M	-$0.63	N/A
Liquidia	$158.32M	23.74	-$68.92M	-$0.83	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paragon 28	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Liquidia	2 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.92

Summary

Liquidia beats Paragon 28 on 9 of the 17 factors compared between the two stocks.

How does Paragon 28 compare to MiniMed Group?

Paragon 28 (NYSE:FNA) and MiniMed Group (NASDAQ:MMED) are both medical equipment companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

: In the previous week, MiniMed Group had 1 more articles in the media than Paragon 28. MarketBeat recorded 1 mentions for MiniMed Group and 0 mentions for Paragon 28. Paragon 28's average media sentiment score of 0.00 beat MiniMed Group's score of -1.05 indicating that Paragon 28 is being referred to more favorably in the media.
Company Overall Sentiment
Paragon 28 Neutral
MiniMed Group Negative
: MiniMed Group has a consensus target price of $22.45, suggesting a potential upside of 91.43%. Given MiniMed Group's stronger consensus rating and higher probable upside, analysts clearly believe MiniMed Group is more favorable than Paragon 28.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Paragon 28
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
MiniMed Group
0 Sell rating(s)

2 Hold rating(s)

11 Buy rating(s)

0 Strong Buy rating(s)
2.85
: MiniMed Group has a net margin of 0.00% compared to Paragon 28's net margin of -25.31%. MiniMed Group's return on equity of 0.00% beat Paragon 28's return on equity.
Company Net Margins Return on Equity Return on Assets
Paragon 28 -25.31% -37.90% -18.22%
MiniMed Group N/A N/A N/A
: MiniMed Group has higher revenue and earnings than Paragon 28.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Paragon 28 $256.18M 4.29 -$57.53M -$0.63 N/A
MiniMed Group $2.99B 1.10 N/A N/A N/A
: 63.6% of Paragon 28 shares are held by institutional investors. Comparatively, 19.7% of MiniMed Group shares are held by institutional investors. 15.3% of Paragon 28 shares are held by company insiders. Comparatively, 2.2% of MiniMed Group shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Company	Overall Sentiment
Paragon 28	Neutral
MiniMed Group	Negative

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Paragon 28	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
MiniMed Group	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85

Company	Net Margins	Return on Equity	Return on Assets
Paragon 28	-25.31%	-37.90%	-18.22%
MiniMed Group	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Paragon 28	$256.18M	4.29	-$57.53M	-$0.63	N/A
MiniMed Group	$2.99B	1.10	N/A	N/A	N/A

Summary

MiniMed Group beats Paragon 28 on 8 of the 12 factors compared between the two stocks.

Get Paragon 28 News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FNA vs. The Competition

Export

Metric	Paragon 28	Surgical & medical instruments Industry	Medical Sector	NYSE Exchange
Market Cap	$1.10B	$47.77M	$6.31B	$23.24B
Dividend Yield	N/A	1.08%	2.77%	4.00%
P/E Ratio	-17.69	15.87	28.68	28.31
Price / Sales	4.29	30.28	527.53	23.82
Price / Cash	N/A	18.88	43.30	25.49
Price / Book	6.39	14.53	9.86	4.67
Net Income	-$57.53M	-$20.10M	$3.55B	$1.07B

Paragon 28 Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FNA Paragon 28	N/A	$13.09 flat	N/A	N/A	$1.10B	$256.18M	N/A	343,000
NVST Envista	2.3195 of 5 stars	$25.91 -2.2%	$28.25 +9.1%	+45.0%	$4.22B	$2.72B	92.52	12,000	Trending News Earnings Report Analyst Forecast Gap Up
IRTC iRhythm Technologies	3.5927 of 5 stars	$120.75 -3.7%	$202.92 +68.1%	-8.4%	$3.97B	$747.14M	N/A	2,400
TMDX TransMedics Group	4.4389 of 5 stars	$98.57 -2.7%	$152.33 +54.5%	-24.0%	$3.40B	$605.49M	20.12	210	Trending News Earnings Report Analyst Downgrade
LQDA Liquidia	2.4429 of 5 stars	$38.15 +1.3%	$43.44 +13.9%	+172.2%	$3.39B	$158.32M	N/A	50	Upcoming Earnings Analyst Upgrade Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:FNA) was last updated on 5/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Paragon 28 (FNA) Competitors

FNA vs. NVST, IRTC, TMDX, LQDA, and MMED

How does Paragon 28 compare to Envista?

Summary

How does Paragon 28 compare to iRhythm Technologies?

Summary

How does Paragon 28 compare to TransMedics Group?

Summary

How does Paragon 28 compare to Liquidia?

Summary

How does Paragon 28 compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNA vs. The Competition

Paragon 28 Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Paragon 28 (FNA) Competitors

FNA vs. NVST, IRTC, TMDX, LQDA, and MMED

How does Paragon 28 compare to Envista?

Summary

How does Paragon 28 compare to iRhythm Technologies?

Summary

How does Paragon 28 compare to TransMedics Group?

Summary

How does Paragon 28 compare to Liquidia?

Summary

How does Paragon 28 compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FNA vs. The Competition

Paragon 28 Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools